We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) (KLL3)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01397916
First Posted: July 20, 2011
Last Update Posted: March 30, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
MSinisalo, Tampere University Hospital
  Purpose
The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL) is studied.

Condition
CLL

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Activity of Indoleamine 2,3-dioxygenase in Patients With Chronic Lymphocytic Leukemia (CLL)

Resource links provided by NLM:


Further study details as provided by MSinisalo, Tampere University Hospital:

Primary Outcome Measures:
  • IDO activity and expression measured by kynurenine/tryptophan ratio in serum and by PCR in peripheral blood mononuclear cells. [ Time Frame: 3 months ]
    Indoleamine 2,3 -dioxygenase (IDO) activity in patients with CLL was measured by the serum kynurenine/tryptophan (kyn/trp) ratio and - the expression of INDO (encoding IDO enzyme) and INDOL1 (encoding IDO2 enzyme) genes in peripheral blood mononuclear cells via TaqMan real-time PCR.


Biospecimen Retention:   Samples With DNA
Ido expression

Enrollment: 73
Study Start Date: February 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
CLL-patients
Controls

Detailed Description:
The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL)is studied in patients and healthly controls.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 85 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with CLL
Criteria

Inclusion Criteria:

  • Patients with CLL and lymphocyte count > 10 x 109/l

Exclusion Criteria:

  • Acute infection
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01397916


Locations
Finland
Tampere university Hospital
Tampere, Finland, 33521
Sponsors and Collaborators
Tampere University Hospital
Investigators
Principal Investigator: Marjatta Sinisalo, MD, PhD Tampere University Hospital
  More Information

Responsible Party: MSinisalo, Dr, Tampere University Hospital
ClinicalTrials.gov Identifier: NCT01397916     History of Changes
Other Study ID Numbers: CLL-IDO
First Submitted: May 18, 2010
First Posted: July 20, 2011
Last Update Posted: March 30, 2012
Last Verified: March 2012

Keywords provided by MSinisalo, Tampere University Hospital:
CLL
IDO

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell


To Top